Loading…
Perspective Therapeutics, Inc. is projected to rise to $3.21 by 2027, a +7% move from its current price of $3.01. CATX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.90 | $3.01 | $3.13 | +0.03% |
| Jul 14 | $2.85 | $3.01 | $3.18 | +0.05% |
| Jul 15 | $2.82 | $3.01 | $3.22 | +0.08% |
| Jul 16 | $2.79 | $3.01 | $3.26 | +0.11% |
| Jul 17 | $2.76 | $3.01 | $3.29 | +0.14% |
| Jul 18 | $2.74 | $3.01 | $3.31 | +0.16% |
| Jul 19 | $2.72 | $3.02 | $3.34 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.72 | $3.02 | $3.34 | +0.19% |
| Week 2 | $2.61 | $3.02 | $3.49 | +0.39% |
| Week 3 | $2.54 | $3.03 | $3.61 | +0.58% |
| Week 4 | $2.47 | $3.03 | $3.72 | +0.77% |
| Week 5 | $2.42 | $3.04 | $3.82 | +0.97% |
| Week 6 | $2.37 | $3.04 | $3.91 | +1.16% |
| Week 7 | $2.33 | $3.05 | $4.00 | +1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidates VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc.
and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Perspective Therapeutics, Inc. trades under the symbol CATX. Its current price is $3.17 and its market cap is $361.53M, with a rank of 3343.
In the near term, the stock's price context includes a 30-day range of $2.46 to $4.08. These figures provide context for the current trading environment and liquidity.
Longer-term forecasts project upside across years, with an average price near $3.17 in 2026 and potential growth toward higher levels later in the decade and into the 2030s and beyond.
A major floor 26.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 34.6% above — a clean break opens room to run.
A major ceiling 77.7% above — clearing it would confirm fresh momentum.
Key CATX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CATX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.32 | Sell | $3.24 | Sell |
| MA 10 | $3.37 | Sell | $3.28 | Sell |
| MA 20 | $3.17 | Sell | $3.29 | Sell |
| MA 50 | $3.49 | Sell | $3.50 | Sell |
| MA 100 | $4.11 | Sell | $3.68 | Sell |
| MA 200 | $3.59 | Sell | $3.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.25 | Neutral |
| Stoch RSI (14) | 17.99 | Buy |
| CCI (20) | -48.10 | Neutral |
| Williams %R (14) | -98.41 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 0.33 | Buy |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 1.59 | Buy |
| TRIX (15) | -0.31 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 34.65 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 3.17 | Sell |
| ADX (14) | 21.43 | Sell |
| ATR (14) | 0.11 | Info |
The near-term technical picture is NEUTRAL, with RSI(14) at 40. The stock trades around its 50-day and 200-day simple moving averages near $3.51 and $3.59, respectively, suggesting limited immediate momentum.
Support sits at $2.93 and resistance at $4.16, with a 30-day price range of $2.46 to $4.08. Annualized volatility is high at 70%, indicating substantial price fluctuation potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.33 | $3.01 | $4.28 | 0% | Neutral | |
| $2.46 | $3.21 | $4.50 | +7% | Neutral | |
| $2.86 | $3.90 | $5.73 | +29% | Bullish | |
| $3.13 | $4.41 | $6.74 | +47% | Bullish | |
| $3.20 | $4.65 | $7.33 | +55% | Bullish | |
| $2.99 | $4.47 | $7.25 | +49% | Bullish | |
| $2.74 | $4.21 | $6.99 | +40% | Bullish | |
| $2.75 | $4.34 | $7.37 | +44% | Bullish | |
| $2.82 | $4.56 | $7.90 | +51% | Bullish | |
| $3.38 | $5.59 | $9.88 | +86% | Bullish | |
| $3.08 | $5.68 | $10.85 | +89% | Bullish | |
| $6.11 | $13.58 | $28.98 | +351% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.33 | $3.01 | $3.61 | +0.00% |
| August 2026 | $2.61 | $3.11 | $3.84 | +3.34% |
| September 2026 | $2.56 | $3.09 | $3.87 | -0.77% |
| October 2026 | $2.48 | $3.02 | $3.83 | -2.24% |
| November 2026 | $2.58 | $3.17 | $4.06 | +4.90% |
| December 2026 | $2.68 | $3.30 | $4.28 | +4.32% |
Click any year to see its month-by-month CATX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Perspective Therapeutics, Inc.'s 2026 outlook centres on $3.01, within a $2.33 to $4.28 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CATX could reach as high as $4.50, with a base case around $3.21 and support toward $2.46 — roughly +7% from $3.01. Price action looks broadly range-bound.
Expect CATX to range from $2.86 to $5.73 through 2028. The $3.90 average target implies a +29% move from current prices. That is up +21% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CATX price prediction for 2029 points to an average of $4.41 (low $3.13, high $6.74) — a potential gain of +47% on today's $3.01. Momentum favours further upside here.
In 2030, CATX is projected to trade between $3.20 and $7.33, averaging $4.65 — a potential gain of +55% from today's $3.01. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Perspective Therapeutics, Inc.'s 2031 outlook centres on $4.47, within a $2.99 to $7.25 range. That is -4% versus the projected 2030 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2032, CATX could reach as high as $6.99, with a base case around $4.21 and support toward $2.74 — roughly +40% from $3.01. Buyers look set to stay in control over this stretch.
Expect CATX to range from $2.75 to $7.37 through 2033. The $4.34 average target implies a +44% move from current prices. That is up +3% on the projected 2032 average. Momentum favours further upside here.
The CATX price prediction for 2034 points to an average of $4.56 (low $2.82, high $7.90) — a potential gain of +51% on today's $3.01. Buyers look set to stay in control over this stretch.
In 2035, CATX is projected to trade between $3.38 and $9.88, averaging $5.59 — a potential gain of +86% from today's $3.01. That is up +23% on the projected 2034 average. Momentum favours further upside here.
Perspective Therapeutics, Inc.'s 2040 outlook centres on $5.68, within a $3.08 to $10.85 range. That is up +2% on the projected 2035 average. That marks a +89% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CATX could reach as high as $28.98, with a base case around $13.58 and support toward $6.11 — roughly +351% from $3.01. Momentum favours further upside here.
Investing $1,000 in CATX today (≈ 332.225914 CATX) could be worth
$4,512.41
+$3,512.41 (+351%) by 2050 · US Dollar
Based on the average projected CATX price of $13.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CATXwould be worth at today's price.
$1,000 invested in CATX on Jul 10, 2025 (≈ 243.308995 CATX) would be worth
$732.36
-$267.64 (-26.8%) today · 0.73× · US Dollar
Based on a CATX entry price of $4.11 vs. today's $3.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.63 | $829.2 | -17.1% |
| 1 month ago | $2.95 | $1,020.34 | +2.0% |
| 3 months ago | $4.47 | $673.38 | -32.7% |
| 6 months ago | $2.41 | $1,248.96 | +24.9% |
| 1 year ago | $4.11 | $732.36 | -26.8% |
| All time (5.0y) ago | $7.4 | $406.76 | -59.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CATX forecast.
Our base-case forecast reaches $6.00 around 2050.
Implied market cap at $6.00: $684.28M
The multi-year forecast shows bullish sentiment emerging in the later years. The 2026 forecast lists min $2.33, avg $3.17, max $4.52, ROI 0, sentiment NEUTRAL. By 2030, the avg is $4.97 with ROI 56.7 and bullish sentiment.
By 2040, the avg is $6.20 with ROI 95.6 and bullish sentiment. By 2050, the avg is $14.85 with ROI 368.3 and bullish sentiment. These estimates illustrate a path of higher prices and sizable upside, but remain probabilistic and not a guarantee.
Tap a question to reveal the answer.
2030 forecast: avg $4.97, min $3.42, max $7.82, ROI 56.7%, sentiment BULLISH.
Forecasts indicate bullish sentiment from 2028 onward, with 2030 avg $4.97 and ROI 56.7%; these are estimates, not guarantees.
2035 max forecast is $10.74, with 2030 avg $4.97 and 2035 max $10.74.
The 30-day price range is $2.46 to $4.08.
Current price $3.17; market cap $361.53M; rank 3343.
Perspective Therapeutics, Inc. Community Discussion
0Share your Perspective Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.